New era in soft tissue repair
Soft-tissue repair has seen limited progress in recent decades, with current options like hydrogels, sponges, and films not providing the ideal microscale architecture for tissue regeneration. Using biological materials, such as xenografts and allografts poses risks of disease transmission, immune rejection, and has limitations in terms of mechanical strength and shelf life. Synthetic biomaterials have been introduced as an alternative, but their degradation mechanisms can cause inflammation and are hard to predict.
Matregenix has developed MatriNova, a new platform technology that utilizes nanofiber technology to create a non-biological, antimicrobial, programmable fiber matrix similar to the human extracellular matrix. Unlike other synthetic materials, MatriNova breaks down into amino acids and does not produce acidic by-products that cause tissue inflammation. This new technology promotes tissue growth while preserving strength and flexibility, presenting a new approach in the $20 billion soft-tissue repair market and shifting away from traditional xenografts and allografts to synthetic tissue-engineered scaffolds.